Sonova Holding AG/€SOON

1D1W1MYTD1Y5YMAX

About Sonova Holding AG

Sonova Holding AG is a Swiss company operating in the healthcare industry, specifically focusing on the development, manufacturing, and distribution of hearing care solutions. Its product portfolio includes hearing aids, cochlear implants, wireless communication devices, and professional audiological care services. Founded in 1947, Sonova is headquartered in Stäfa, Switzerland, and serves a global market with its products available in over 100 countries. The company distinguishes itself through continuous innovation in audiological technology and an integrated approach to hearing healthcare, providing both advanced products and comprehensive support services. Sonova’s strategic positioning is enhanced by its focus on research and development, as well as a robust distribution network that includes a mix of retail and wholesale channels.
Ticker
€SOON
Sector
Health
Primary listing
XGAT
Employees
18,580
Headquarters
Stäfa, Switzerland

SOON Metrics

BasicAdvanced
€14B
31.60
€7.64
1.07
€5.10
2.11%

Bulls say / Bears say

Sonova delivered a robust FY 2025/26 performance, with group sales up 5.9% in local currencies to CHF 3,605.9 million and normalized EBITA rising 17.3% to CHF 811.2 million, driving the EBITA margin to 22.5% on strong operating leverage and market-share gains ([Sonova], [turn2search5]).
For FY 2026/27, Sonova forecasts sales growth of 5–8% and core EBIT expansion of 7–10%, underpinned by a new AI-driven platform launch in H2 2026 to sustain its leadership in premium hearing solutions ([Reuters], [turn1view0]).
The partnership with the Singapore Economic Development Board to establish an Innovation Center for Affordable Hearing Solutions in Singapore bolsters Sonova’s R&D and manufacturing footprint in the high-growth Asia-Pacific market, supporting its medium-term growth ambitions ([EDB], [turn4search0]).
Cochlear Implants segment continues to underperform, with sales down 11.1% in local currencies and normalized EBITA margin plunging to 6.8%, as the business grapples with China’s volume-based procurement and intensified competitor launches ([Sonova], [turn7view0]).
Pronounced foreign-exchange headwinds are set to trim reported growth, with FX expected to shave off 1–2 percentage points of sales and 3–4 points of core EBIT in FY 2026/27, adding volatility to reported Swiss-franc results ([Sonova], [turn7view0]).
Shortening product and platform cycles amid escalating competition demand ever-higher R&D investment, risking margin compression if Sonova cannot refresh its portfolio as frequently as peers advancing AI integration ([Reuters], [turn1view0]).
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2026.

Funds containing SOON

Funds
Fund name
Fund size
€SOON weighting
WisdomTree Global Quality Dividend Growth£GGRG
£1.9B0.07%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.